세계의 COVID-19 백신 시장(2025-2033년)

The global COVID-19 vaccine market reached US$ 13.43 billion in 2024 and is expected to reach US$ 29.98 billion by 2033, growing at a CAGR of 9.8% during the forecast period 2025-2033.

The global COVID-19 vaccine market encompasses the entire ecosystem involved in the development, manufacturing, distribution, and administration of vaccines specifically designed to prevent COVID-19, which is caused by the SARS-CoV-2 virus. This market includes several types of vaccines, such as mRNA-based vaccines these innovative vaccines utilize messenger RNA to instruct cells to produce a protein that triggers an immune response. Notable examples include the Pfizer-BioNTech and Moderna vaccines.

Viral vector vaccines employ a harmless virus as a delivery system to introduce genetic material from the SARS-CoV-2 virus into human cells. A prominent example of this type is the Johnson & Johnson vaccine and protein subunit vaccines consist of harmless pieces of the virus (proteins) rather than the entire pathogen, which helps stimulate an immune response without causing disease. These factors have driven the global COVID-19 vaccine market expansion.

Market Dynamics: Drivers & Restraints

Government Support and Initiatives

Government support and initiatives are pivotal in shaping the global COVID-19 vaccine market. These efforts are crucial for accelerating vaccine development, ensuring equitable distribution, and enhancing public health responses.

Governments around the world have made substantial financial commitments to support the research, development, and distribution of COVID-19 vaccines. For instance, the U.S. government invested billions through programs like Operation Warp Speed, which aimed to expedite vaccine development while ensuring safety and efficacy. Similar financial support has been provided by other countries, facilitating large-scale clinical trials and manufacturing capabilities.

Governments have fostered collaborations between public entities and private pharmaceutical companies to share resources, expertise, and risks associated with vaccine development. These partnerships have enabled rapid innovation and scaling of production capacities, ensuring that vaccines can be manufactured in sufficient quantities to meet global demand. Government agencies, such as the FDA in the U.S. and the EMA in Europe, have implemented expedited review processes for COVID-19 vaccines. This regulatory flexibility has allowed for quicker approvals while maintaining rigorous safety standards, thereby accelerating the timeline from development to public availability.

Furthermore, key players in the industry more focus on innovative treatments for COVID-19, awareness programs, and government initiatives that would drive this global COVID-19 vaccine market growth. For instance, in July 2024, the National Institutes of Health (NIH) initiated a Phase 1 clinical trial for an investigational nasal COVID-19 vaccine called MPV/S-2P. This vaccine is designed to enhance protection against emerging variants of the SARS-CoV-2 virus, which causes COVID-19.

Also, in October 2024, the Centers for Disease Control and Prevention (CDC) recommended that individuals aged 65 years and older, as well as those who are moderately or severely immunocompromised, receive a second dose of the 2024-2025 COVID-19 vaccine. This second dose should be administered six months after the previous dose. All these factors demand the global COVID-19 vaccine market.

Similarly, in August 2024, the Government of India implemented several proactive measures to enhance preparedness for future pandemics, particularly in light of the lessons learned from the COVID-19 pandemic. A crucial aspect of this preparedness strategy involves providing financial assistance to states and Union Territories (UTs) to strengthen their healthcare capabilities. Moreover, the rising demand for the emergence of new variant monitoring contributes to the global COVID-19 vaccine market expansion.

Limited Manufacturing Capacity

The limited manufacturing capacity will hinder the growth of the global COVID-19 vaccine market. The vaccine manufacturing landscape is highly concentrated, with a small number of manufacturers responsible for a large share of global vaccine production. For example, approximately ten manufacturers account for around 70% of vaccine doses worldwide. This concentration creates vulnerabilities in supply chains and can lead to shortages and regional supply insecurity, particularly affecting lower-income countries that rely on external sources for their vaccines.

The production of vaccines requires various raw materials, including glass vials, rubber stoppers, and other essential components for packaging and administering vaccines. Shortages of these critical materials can significantly disrupt production timelines. For instance, during the pandemic, there were notable shortages of natural rubber used for gloves and stoppers, which are vital for safe vaccine administration.

Vaccine manufacturing is technically demanding and complex, requiring sophisticated equipment and specialized knowledge. The intricate nature of biological production means that many manufacturers are ill-prepared for rapid scaling during health crises, making it challenging to respond effectively when new threats arise. Thus, the above factors could be limiting the global COVID-19 vaccine market's potential growth.

Segment Analysis

The global COVID-19 vaccine market is segmented based on infection type, vaccine type, route of administration, age group, end-user, and region.

Vaccine Type:

The mRNA Vaccines segment is expected to dominate the global COVID-19 vaccine market share

The mRNA vaccines segment holds a major portion of the global COVID-19 vaccine market share and is expected to continue to hold a significant portion of the global COVID-19 vaccine market share during the forecast period.

The mRNA vaccines for COVID-19, namely the Pfizer-BioNTech and Moderna vaccines, represent a groundbreaking method for eliciting an immune response against the virus. These vaccines contain synthetic messenger RNA (mRNA) that provides the genetic instructions for producing the spike (S) protein, a key component on the surface of the SARS-CoV-2 virus responsible for COVID-19. Upon administration, the mRNA enters muscle cells at the injection site, where it begins its role in protein synthesis.

Inside the cells, the mRNA is translated by ribosomes into the spike protein. This translation process allows the cells to produce harmless pieces of the spike protein, which are essential for triggering an immune response. The spike proteins generated by the cells are displayed on their surfaces. The immune system identifies these proteins as foreign invaders, which activates various immune responses. This includes the mobilization of T-cells and B-cells, leading to the production of specific antibodies that target the spike protein.

Furthermore, key players in the industry more focus on clinical trails and getting positive results that would propel this segment's growth in the global COVID-19 vaccine market. For instance, in June 2024, Moderna, Inc. announced that its Phase 3 trial for the investigational next-generation COVID-19 vaccine, mRNA-1283, has successfully met its primary efficacy endpoint. The trial demonstrated that mRNA-1283 exhibits non-inferior vaccine efficacy against COVID-19 compared to Moderna's previously authorized vaccine, Spikevax (mRNA-1273). These factors have solidified the segment's position in the global COVID-19 vaccine market.

Geographical Analysis

North America is expected to hold a significant position in the global COVID-19 vaccine market share

North America holds a substantial position in the global COVID-19 vaccine market and is expected to hold most of the market share.

Growing public understanding of the benefits of vaccination has led to heightened demand for COVID-19 vaccines. This awareness is crucial in driving vaccination campaigns and improving uptake rates across various demographics. Significant investments from governments and international organizations are enhancing vaccination efforts. This funding not only supports the development and distribution of vaccines but also funds public health campaigns aimed at promoting vaccination.

Advances in vaccine technology, particularly mRNA technology, have improved the efficiency of vaccine production and distribution. Companies like Pfizer and Moderna have expanded their manufacturing capabilities, contributing to increased vaccine availability. North America benefits from a well-established healthcare infrastructure that facilitates effective vaccine distribution. Advanced cold chain logistics ensure that vaccines are stored and transported under optimal conditions, preserving their efficacy throughout the supply chain.

The continuous emergence of new variants of the virus necessitates ongoing vaccination efforts, including booster doses. This drives market growth as populations seek updated vaccines to combat these variants. Continuous research and development initiatives by pharmaceutical companies are vital for creating next-generation vaccines. For example, Moderna's establishment of a new R&D hub in Toronto focuses on mRNA technologies, reinforcing North America's position as a center for vaccine innovation.

Furthermore, in this region a major number of key players presence, digital innovations for COVID-19, and government major initiatives that would drive the global COVID-19 vaccine market growth. For instance, in August 2024, Pfizer Inc. unveiled PfizerForAll, a digital platform designed to streamline access to healthcare and wellness services for individuals across the United States. This innovative platform aims to assist millions of Americans dealing with common health issues such as migraines, COVID-19, and the flu, while also facilitating adult vaccinations.

Also, in August 2024, Health Canada is currently reviewing new COVID-19 vaccines from Pfizer, Moderna, and Novavax that specifically target emerging Omicron subvariants, including KP.2. This assessment follows recent approvals in the United States and is part of Canada's ongoing efforts to address waning immunity in the population and the spread of new variants, which pose heightened risks, particularly to vulnerable groups. Thus, the above factors are consolidating the region's position as a dominant force in the global COVID-19 vaccine market.

Asia Pacific is growing at the fastest pace in the global COVID-19vaccine market share

Asia Pacific holds the fastest pace in the global COVID-19 vaccine market and is expected to hold most of the market share.

Governments across the Asia Pacific are making significant investments in vaccine development and distribution. For instance, Australia has committed AU$18 billion to its vaccine strategy, Thailand has allocated $2.16 billion for vaccine procurement and distribution, and China is investing $4 billion in next-generation vaccine research. The persistent need for COVID-19 vaccinations, including booster doses, continues to drive demand. Countries such as Vietnam, Thailand, and the Philippines have placed large orders to support their vaccination efforts, demonstrating a strong commitment to public health.

Innovations in vaccine technology, particularly the rapid development of mRNA vaccines during the pandemic, have improved production efficiency and effectiveness. The success of these vaccines has led to increased interest and investment in similar technologies. The healthcare systems in the region are evolving, with initiatives like Malaysia's $500 million Vaccine Logistics Hub aimed at optimizing vaccine distribution across the ASEAN region. Efficient supply chains are crucial for meeting the high demand for vaccines.

Furthermore, major players in the industry launched key initiatives that would drive this global COVID-19 vaccine market growth. For instance, in June 2023, Union Minister of State (Independent Charge) for Science and Technology, Dr. Jitendra Singh, launched GEMCOVAC-OM, marking India's first mRNA-based booster vaccine specifically designed to combat the Omicron variant of COVID-19. This development follows the vaccine's recent receipt of Emergency Use Authorization (EUA) from the Drugs Controller General of India (DCGI).

Also, in September 2024, Indian Immunologicals Ltd (IIL), based in Hyderabad, announced the development of a needle-free intranasal booster vaccine targeting SARS-CoV-2. This innovative vaccine was created in collaboration with Griffith University in Australia and represents a significant step forward in enhancing vaccination strategies against COVID-19. Thus, the above factors are consolidating the region's position as the fastest-growing force in the global COVID-19 vaccine market.

Competitive Landscape

The major global players in the COVID-19 vaccine market include Pfizer/BioNTech, Moderna, Inc., AstraZeneca., Johnson & Johnson (Janssen Scientific Affairs, LLC), SINOVAC, CanSino Biologics Inc., Novavax., Sanofi/GSK, Beijing Institute of Biological Products Co., Ltd., Serum Institute of India Pvt. Ltd., and Gamaleya Research Institute among others.

Key Developments

• In January 2025, the U.S. Food and Drug Administration (FDA) approved and granted emergency use authorization (EUA) for updated mRNA COVID-19 vaccines designed for the 2024-2025 season. These vaccines now incorporate a monovalent (single) component specifically targeting the Omicron variant KP.2 strain of SARS-CoV-2.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global COVID-19 vaccine market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Infection Type
• 3.2. Snippet by Vaccine Type
• 3.3. Snippet by Route of Administration
• 3.4. Snippet by Age Group
• 3.5. Snippet by End-User
• 3.6. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Government Support and Initiatives
  • 4.1.2. Restraints
    • 4.1.2.1. Limited Manufacturing Capacity
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Unmet Needs

6. By Infection Type

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Infection Type
  • 6.1.2. Market Attractiveness Index, By Infection Type
• 6.2. SARS-CoV-2*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. HCoVs
• 6.4. Others

7. By Vaccine Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
  • 7.1.2. Market Attractiveness Index, By Vaccine Type
• 7.2. mRNA Vaccines*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Viral Vector Vaccines
• 7.4. Inactivated Virus Vaccines
• 7.5. Protein Subunit Vaccines
• 7.6. Live Attenuated Vaccines
• 7.7. Others

8. By Route of Administration

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 8.1.2. Market Attractiveness Index, By Route of Administration
• 8.2. Intramuscular*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Subcutaneous
• 8.4. Oral

9. By Age Group

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 9.1.2. Market Attractiveness Index, By Age Group
• 9.2. Below 18 Years*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Above 18 Years

10. By End-User

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.1.2. Market Attractiveness Index, By End-User
• 10.2. Hospitals *
  • 10.2.1. Introduction
  • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 10.3. Specialty Clinics
• 10.4. Others

11. By Region

• 11.1. Introduction
  • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 11.1.2. Market Attractiveness Index, By Region
• 11.2. North America
  • 11.2.1. Introduction
  • 11.2.2. Key Region-Specific Dynamics
  • 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
  • 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
  • 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.2.8.1. U.S.
    • 11.2.8.2. Canada
    • 11.2.8.3. Mexico
• 11.3. Europe
  • 11.3.1. Introduction
  • 11.3.2. Key Region-Specific Dynamics
  • 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
  • 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
  • 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.3.8.1. Germany
    • 11.3.8.2. U.K.
    • 11.3.8.3. France
    • 11.3.8.4. Spain
    • 11.3.8.5. Italy
    • 11.3.8.6. Rest of Europe
• 11.4. South America
  • 11.4.1. Introduction
  • 11.4.2. Key Region-Specific Dynamics
  • 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
  • 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
  • 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.4.8.1. Brazil
    • 11.4.8.2. Argentina
    • 11.4.8.3. Rest of South America
• 11.5. Asia-Pacific
  • 11.5.1. Introduction
  • 11.5.2. Key Region-Specific Dynamics
  • 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
  • 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
  • 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 11.5.8.1. China
    • 11.5.8.2. India
    • 11.5.8.3. Japan
    • 11.5.8.4. South Korea
    • 11.5.8.5. Rest of Asia-Pacific
• 11.6. Middle East and Africa
  • 11.6.1. Introduction
  • 11.6.2. Key Region-Specific Dynamics
  • 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Infection Type
  • 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Vaccine Type
  • 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
  • 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Age Group
  • 11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

• 12.1. Competitive Scenario
• 12.2. Market Positioning/Share Analysis
• 12.3. Mergers and Acquisitions Analysis

13. Company Profiles

• 13.1. Pfizer/BioNTech*
  • 13.1.1. Company Overview
  • 13.1.2. Product Portfolio
    • 13.1.2.1. Product Description
    • 13.1.2.2. Product Key Performance Indicators (KPIs)
    • 13.1.2.3. Historic and Forecasted Product Sales
    • 13.1.2.4. Product Sales Volume
  • 13.1.3. Financial Overview
    • 13.1.3.1. Company Revenue's
    • 13.1.3.2. Geographical Revenue Shares
    • 13.1.3.3. Revenue Forecasts
  • 13.1.4. Key Developments
    • 13.1.4.1. Mergers & Acquisitions
    • 13.1.4.2. Key Product Development Activities
    • 13.1.4.3. Regulatory Approvals etc.
  • 13.1.5. SWOT Analysis
• 13.2. Moderna, Inc.
• 13.3. AstraZeneca.
• 13.4. Johnson & Johnson (Janssen Scientific Affairs, LLC)
• 13.5. SINOVAC
• 13.6. CanSino Biologics Inc.
• 13.7. Novavax.
• 13.8. Sanofi/GSK
• 13.9. Beijing Institute of Biological Products Co., Ltd.
• 13.10. Serum Institute of India Pvt. Ltd.
• 13.11. Gamaleya Research Institute

LIST NOT EXHAUSTIVE

14. Appendix

• 14.1. About Us and Services
• 14.2. Contact Us